Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals

292.75
+29.46
(11.19%)
Market Cap
1,947.60 Cr
EPS
8.26
PE Ratio
45.64
Dividend Yield
0.85 %
Industry
Healthcare
52 Week High
328.04
52 Week Low
139.90
PB Ratio
8.11
Debt to Equity
0.04
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%

Company News

View All News
Caret
neutral
Jagsonpal Pharmaceuticals Makes Q1 FY26 Earnings Call Recording Available Online13 hours ago
Jagsonpal Pharmaceuticals Limited has made the audio recording of their Q1 FY26 earnings conference call available on their company website. The call was held on July 28, 2025 at 3:00 P.M. to discuss Q1 FY26 financial results. The recording can be accessed through the investor relations section of the company's website at their earnings calls page.
positive
Jagsonpal Pharmaceuticals Ltd reported net profit of 107 million rupees for Q1, representing a significant increase from 53 million rupees in the same quarter last year and 65 million rupees in the previous quarter. The company's revenue reached 756 million rupees, up from 614 million rupees year-on-year and 585 million rupees quarter-on-quarter, indicating growth across both timeframes.
neutral
Jagsonpal Pharmaceuticals Reports Quarterly Results with CFO Transition2 days ago
Jagsonpal Pharmaceuticals Limited announced its unaudited financial results for the quarter ended June 30, 2025. The pharmaceutical company, which manufactures and trades pharmaceutical products including active pharmaceutical ingredients in India and overseas, reported basic earnings per share of Rs. 1.60 for the quarter. The company granted 37,500 stock options to eligible employees and allotted 127,850 equity shares under its Employee Stock Option Plan 2022. The Board of Directors recommended a final dividend of Rs. 2.5 per equity share for the year ended March 31, 2025, subject to shareholder approval. Sachin Jain ceased to be the Chief Financial Officer on July 8, 2025, following his release during the probation period, and the company is in the process of hiring a new CFO.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,702.20
#1 4,08,414.80
35.66
#1 54,729.00
12.06
#1 10,980
-18.99
55.97
6,584.00
1,74,784.50
79.73
9,712.00
0.89
2,191
23.05
40.37
1,572.00
1,26,971.70
23.53
28,409.50
7.12
5,291
9.88
70.77
3,622.90
1,22,615.40
60.75
11,539.40
6.99
1,911
19.91
72.46
1,287.40
1,07,442.70
#1 18.90
33,741.20
16.73
5,725
1.26
54.50
2,541.60
1,04,899.10
60.41
12,744.20
19.57
2,007
-10.91
52.39
980.10
98,621.00
21.20
23,511.00
13.82
4,615
-0.19
54.96
1,960.50
89,535.10
27.57
22,909.50
#1 19.94
3,306
#1 112.49
53.75
32,895.00
69,899.60
49.39
6,684.70
10.80
1,414
27.83
42.22
1,127.00
65,456.30
18.95
31,378.10
17.55
3,366
-0.50
47.15
Forecast
Actual
Growth Rate
Revenue Growth
-10.07 %
Net Income Growth
-15.73 %
Cash Flow Change
-24.62 %
ROE
-28.72 %
ROCE
-26.33 %
EBITDA Margin (Avg.)
-9.79 %

Yearly Financial Results

Annual Financials
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
Revenue
138
144
144
127
168
161
192
221
242
218
269
316
Expenses
129
132
138
138
158
150
169
193
203
186
218
228
EBITDA
9
13
6
-11
11
11
24
29
40
32
51
88
Operating Profit %
6 %
8 %
4 %
-9 %
6 %
5 %
10 %
12 %
14 %
11 %
19 %
19 %
Depreciation
3
3
2
0
1
1
1
2
1
2
8
9
Interest
5
5
3
1
1
1
1
0
0
1
1
1
Profit Before Tax
2
4
14
-12
9
9
22
27
35
30
70
77
Tax
1
1
3
-0
2
2
5
8
8
7
14
15
Net Profit
1
3
12
-12
7
8
17
19
27
23
56
61
EPS in ₹
0.45
1.24
4.53
-4.41
2.75
3.00
6.51
7.20
10.20
8.49
8.26
11.60

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
154
159
143
130
136
147
164
164
195
217
278
Fixed Assets
52
52
22
21
22
22
26
23
24
9
94
Current Assets
96
101
110
95
98
95
121
109
165
199
161
Capital Work in Progress
0
0
0
3
4
4
0
0
0
0
0
Investments
0
0
0
0
0
11
15
51
1
0
15
Other Assets
102
108
121
106
110
109
123
91
170
208
0
Total Liabilities
154
159
143
130
136
147
164
164
195
217
278
Current Liabilities
55
57
29
29
28
33
40
27
28
19
26
Non Current Liabilities
4
4
3
3
3
3
2
5
9
11
12
Total Equity
95
98
110
98
105
111
122
133
159
187
240
Reserve & Surplus
82
85
97
85
91
98
109
120
146
174
227
Share Capital
13
13
13
13
13
13
13
13
13
13
13

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
2
1
5
-6
24
-1
19
-36
-12
2
Investing Activities
-1
-2
41
-3
-1
-11
-2
-26
-58
-25
Operating Activities
4
9
-3
-2
31
11
28
7
47
35
Financing Activities
-1
-6
-34
-1
-6
-1
-7
-18
-1
-9

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
70.34 %
70.34 %
70.34 %
70.34 %
68.71 %
68.71 %
68.71 %
68.71 %
68.71 %
68.71 %
68.71 %
68.48 %
68.09 %
68.04 %
67.97 %
67.81 %
67.78 %
67.65 %
FIIs
0.00 %
0.00 %
0.11 %
0.20 %
0.00 %
0.00 %
0.13 %
0.00 %
0.00 %
0.00 %
0.38 %
0.00 %
0.73 %
1.10 %
2.30 %
2.10 %
2.10 %
2.18 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.28 %
0.77 %
0.83 %
0.83 %
0.83 %
0.00 %
0.85 %
0.85 %
0.11 %
0.00 %
0.00 %
0.05 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
26.67 %
26.08 %
23.71 %
23.71 %
22.92 %
25.27 %
22.78 %
21.11 %
22.23 %
22.84 %
21.99 %
21.94 %
20.69 %
20.79 %
20.38 %
20.64 %
20.94 %
24.26 %
Others
2.98 %
3.57 %
5.83 %
5.75 %
8.36 %
6.02 %
8.10 %
9.40 %
8.23 %
7.62 %
8.09 %
9.58 %
9.64 %
9.22 %
9.24 %
9.45 %
9.17 %
5.86 %
No of Share Holders
0
12,546
14,655
14,353
20,031
17,100
16,194
14,952
14,084
13,782
16,041
15,785
16,282
15,748
15,633
18,471
21,085
22,899

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.1 0.1 0.1 0.25 0.5 1 4 5 5 0.00
Dividend Yield (%) 0.66 0.93 0.95 3.56 1.57 0.8 3.45 4.52 2.3 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
24 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
24 Sept 2025 263.29 292.55
26 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
26 Jul 2025 262.50 263.29
06 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 May 2025 232.50 250.05
22 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
22 Jan 2025 215.25 222.00
23 Oct 2024 SPLIT Split
2:5
08 Jan 2025 183.76 183.76
23 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Oct 2024 181.68 183.76
18 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
18 Sept 2024 144.54 164.02
06 Sept 2024 DIVIDEND Dividend
₹ 5.00 /share
06 Sept 2024 144.42 167.08
21 Aug 2023 DIVIDEND Dividend
₹ 5.00 /share
21 Aug 2023 141.58 183.34
17 Jun 2022 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
17 Jun 2022 118.24 111.40
01 Nov 2021 DIVIDEND Dividend
₹ 4.00 /share
29 Oct 2021 64.98 69.88
24 Sept 2021 DIVIDEND Dividend
₹ 1.00 /share
22 Sept 2021 61.54 61.64

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome14 hours ago
Announcement under Regulation 30 (LODR)-Newspaper Publication20 hours ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release2 days ago
Announcement under Regulation 30 (LODR)-Investor Presentation2 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release2 days ago
Announcement under Regulation 30 (LODR)-Investor Presentation2 days ago
The 46Th Annual General Meeting Of The Company Will Be Held On September 24 2025 Dividend- Record Date Will Be September 12 2025 2 days ago
Results- Financial Results For The Quarter Ended June 30 20252 days ago
Board Meeting Outcome for Outcome Of Board Meeting Along With Unaudited Financial Results For The Quarter Ended June 30 20252 days ago
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS4 days ago
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS4 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
Board Meeting Intimation for Consideration And Approval Of Un- Audited Financial Results For The Quarter Ended June 30 20255 days ago
Announcement under Regulation 30 (LODR)-CessationJul 08, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2025
Closure of Trading WindowJun 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 16, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 11, 2025
Announcement under Regulation 30 (LODR)-Change in Registered Office AddressJun 02, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 13, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 08, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 07, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 06, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 06, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 06, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 06, 2025
Termination Of Business Transfer Agreement - Disclosure Under Regulation 30 Of SEBI Listing RegulationsMay 06, 2025
Corporate Action-Board approves DividendMay 06, 2025
Audited (Standalone) Financial Results For The Year Ended March 31 2025May 06, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On May 06 2025 Along With Audited (Standalone) Financial Results For The Quarter And Year Ended March 31 2025May 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 30, 2025
Board Meeting Intimation for Consideration Of Financial Results For The Quarter And Year Ended March 31 2025 And Recommendation Of Dividend If Any For The Financial Year Ended March 31 2025.Apr 29, 2025
Clarification On Significant Increase In The VolumeApr 28, 2025
Clarification On Significant Increase In Volume Of Security Of The Company Required By NSEApr 28, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSApr 21, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 08, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Apr 02, 2025
Closure of Trading WindowMar 26, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 13, 2025
Intimation Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Mar 13, 2025
Appointment of Company Secretary and Compliance OfficerMar 13, 2025
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerMar 03, 2025
Clarification In Reference To The Corporate Announcement Filed Under Regulation 30 Of SEBI (LODR) Regulations 2015 Dated February 21 2025Feb 27, 2025
Announcement under Regulation 30 (LODR)-AcquisitionFeb 21, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI LODR)Feb 21, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 17, 2025
Intimation Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI LODR)Feb 05, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 05, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJan 29, 2025

Technical Indicators

RSI(14)
Neutral
73.31
ATR(14)
Volatile
14.73
STOCH(9,6)
Neutral
72.02
STOCH RSI(14)
Neutral
54.79
MACD(12,26)
Bullish
3.95
ADX(14)
Strong Trend
33.60
UO(9)
Bearish
54.19
ROC(12)
Uptrend And Accelerating
27.09
WillR(14)
Overbought
-11.76

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
0.00%
0
0.00%
0.00%